T2 Biosystems

T2 Biosystems, Inc. engages in the development of a proprietary technology platform. It offers the T2 Magnetic Resonance technology, which enables detection of pathogens, biomarkers, and other abnormalities in a range of unpurified patient sample types. The firm's products include the T2Dx Instrument, the T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

T2 Biosystems, Inc. is a vitro diagnostics company, which engages in the development of detection of sepsis-causing pathogens. It offers T2Dx instrument, T2Bacteria, T2Candida, T2Biothreat panels, and T2MR technology. The company was founded by Michael J. Cima, Robert S. Langer Jr., Tyler Jacks, Lee Josephson, W. David Lee, and Ralph Weissleder on April 27, 2006 and is headquartered in Lexington, MA.

T2 Biosystems, Inc.'s (TTOO) CEO John Sperzel on Q1 2021 Results - Earnings Call Transcript

Shares of T2 Biosystems (NASDAQ:TTOO) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 68.18% year over year to ($0.07), which were in line with the estimate of ($0.07).

Recap: T2 Biosystems Q1 Earnings

Speeds Up Development of T2Biothreat, T2Resistance, Comprehensive Sepsis Panel, Next-Generation Instrument Speeds Up Development of T2Biothreat, T2Resistance, Comprehensive Sepsis Panel, Next-Generation Instrument

T2 Biosystems Accelerates Product Development Initiatives Under Existing BARDA Contract

Cinedigm

ZW Data Action Technologies Inc.

With penny stocks, knowing the most popular industries can make your watchlist competitive with the best traders out there The post Penny Stocks to Buy; The Most Popular Industries Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks to Buy; The Most Popular Industries Right Now

LEXINGTON, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the first quarter of 2021 after market close on Thursday, May 6, 2021. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

T2 Biosystems to Report First Quarter 2021 Financial Results on May 6, 2021

Aikido Pharma Inc.

Iterum Therapeutics Plc

Ovid Therapeutics

Biotech penny stocks are all the rage; should you check these four out? The post 4 Biotech Penny Stocks To Watch That Are Heating Up This Month appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Biotech Penny Stocks To Watch That Are Heating Up This Month

All proceeds from the book sale will be donated to Sepsis Alliance and Donate Life America

T2 Biosystems CEO Shares Personal Heart Transplant and Sepsis Survival Story in Newly Released Book

New York, New York--(Newsfile Corp. - March 15, 2021) - Levi & Korsinsky announces it has commenced an investigation of T2 Biosystems, Inc. (NASDAQ: TTOO) concerning possible breaches of fiduciary duty. To obtain additional information, go to:https://www.zlk.com/compensation2/t2-biosystems-inc-information-request-formor contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of T2 Biosystems, Inc. (TTOO)

T2 Biosystems, Inc. (TTOO) CEO John Sperzel on Q4 2020 Results - Earnings Call Transcript

T2 Biosystems (TTOO) delivered earnings and revenue surprises of -16.67% and 0.08%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

T2 Biosystems (TTOO) Reports Q4 Loss, Tops Revenue Estimates

Fulgent Genetics

Strong earnings sent both of these healthcare stocks higher after hours on Thursday.

These 2 Stocks Are Soaring Despite Another Market Plunge

Shares of T2 Biosystems (NASDAQ:TTOO) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 76.67% year over year to ($0.07), which were in line with the estimate of ($0.07).

Recap: T2 Biosystems Q4 Earnings

LEXINGTON, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the fourth quarter and full year ended December 31, 2020.

T2 Biosystems Announces Fourth Quarter & Full Year 2020 Financial Results

Ideanomics Inc

If January and February are a sign of things to come in 2021, traders and investors are going to make a lot of money this year. 4 penny stocks to watch are Bantec (OTCMKTS: BANT), Cielo Waste Solutions (OTCMKTS: CWSFF), Ideanomics (NASDAQ: IDEX), and T2 Biosystems (NASDAQ: TTOO).

4 Penny Stocks To Watch: Bantec (OTC US: BANT), Cielo Waste Solutions (OTC US: CWSFF), Ideanomics (NASDAQ: IDEX), and T2 Biosystems (NASDAQ: TTOO)

T2 Biosystems is an innovative medical company set to thrive long term. As with every small biotech, there will be extreme volatility along the way.

One Possible Play On T2 Biosystems Given The Increasing Market Volatility

LEXINGTON, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate in the upcoming BTIG Virtual MedTech, Digital Health, Life Science & Diagnostics Tools Conference.

T2 Biosystems to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostics Tools Conference

The diagnostic test maker's panels could help to combat the spread of new coronavirus variants.

Why T2 Biosystems Stock Soared Today

TTOO stock is climbing on Friday after T2 Biosystems announced its Covid-19 test can detect the Brazilian strain. What should you know?

TTOO Stock: Why T2 Biosystems Is Shooting Higher Today

The stock price of T2 Biosystems Inc (NASDAQ: TTOO) is trading at over 60% pre-market as of 4:52 AM ET. This is why it happened.

TTOO Stock Price Increases Over 60% Pre-Market: Why It Happened

Panel is capable of detecting 99.99% of all currently identified SARS-CoV-2 viruses based on sequence alignments and in silico analysis

T2 Biosystems T2SARS-CoV-2™ Panel Proves Capable of Detecting the Brazil P.1 Variant of the SARS-CoV-2 Virus

Strengthens Balance Sheet Through Amendment of Loan Agreement with CRG Strengthens Balance Sheet Through Amendment of Loan Agreement with CRG

T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2020 Results

T2 has been a huge beneficiary of the COVID-19 pandemic, as hospitals take a second look at its revolutionary diagnostic technology. A 300% revenue gain is projected by Wall Street for 2021 vs. 2019.

T2 Biosystems: Last Year's R&D Setup Morphing Into Leading 2021 Growth Pick

The stock price of T2 Biosystems Inc (NASDAQ: TTOO) increased by 18.75% as it went from a previous close of $1.60 to $1.90. This is why it happened.

TTOO Stock Price Increases 18.75%: Why It Happened

Investors are excited about the prospects of the company's COVID-19 diagnostic test.

Why T2 Biosystems Stock Is Soaring Today

Amneal Pharmaceuticals

BeiGene

BeiGene (NASDAQ: BGNE) shares are trading higher after on Tuesday after the company announced a collaboration agreement with Novartis to developed and commercialize Anti-PD-1 antibody Tislelizumab. BeiGene will receive $650 million upfront and is eligible to receive up to $1.55 billion in milestone payments.

News for T2 Biosystems Stock (TTOO)